V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210003036 | 210010360 | null | 79.4 | Adjuvant (A) | null | 2021-10-20 | Docetaxel | null | N | DOCETAXEL | 101077034 |
| 210003037 | 210010361 | 1.6 | 86.5 | Palliative (P) | null | 2019-07-30 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 101449331 |
| 210003043 | 210010364 | 1.63 | null | Palliative (P) | 2018-02-09 | 2018-06-05 | Docetaxel | null | N | DOCETAXEL | 100052869 |
| 210003047 | 210010365 | null | null | null | null | 2017-02-08 | Trastuzumab | 02 | null | TRASTUZUMAB | 101063761 |
| 210003050 | 210010366 | 1.66 | 78.5 | Adjuvant (A) | 2018-03-30 | 2018-06-11 | Trastuzumab | 02 | N | TRASTUZUMAB | 101216599 |
| 210003053 | 210010367 | null | 84.4 | null | 2021-02-22 | 2021-03-09 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100836399 |
| 210003055 | 210010368 | null | null | null | 2016-02-21 | 2017-03-31 | EC | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101391093 |
| 210003057 | 210010369 | 1.58 | 65.7 | Adjuvant (A) | 2019-10-16 | 2019-11-04 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100576686 |
| 210003060 | 210010371 | null | 103 | Adjuvant (A) | 2016-06-19 | 2016-06-21 | Paclitaxel 7 day | 02 | N | PACLITAXEL | 100109764 |
| 210003062 | 210010372 | 1.65 | 60.2 | Adjuvant (A) | null | 2020-05-04 | PACLITAXEL | 02 | null | PACLITAXEL | 100579457 |
| 210003066 | 210010374 | 1.7 | 61.4 | Palliative (P) | 2019-12-22 | 2019-12-22 | TCH (21 day Trastuzumab) Maint | 02 | N | CARBOPLATIN + DOCETAXEL | 100325285 |
| 210003067 | 210010375 | 1.7 | 62.4 | Neo-adjuvant (N) | 2019-03-14 | 2019-04-18 | Doce + Pertuzumab + Trastuz IV Load | null | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101080806 |
| 210003068 | 210010376 | 0 | null | Palliative (P) | 2018-08-26 | 2018-12-03 | Capecitabine | null | N | FULVESTRANT + PALBOCICLIB | 100586804 |
| 210003070 | 210010377 | 1.67 | 92.2 | Adjuvant (A) | null | 2020-09-01 | PERTUZUMAB + TRASTUZUMAB | 02 | N | PERTUZUMAB + TRASTUZUMAB | 100030471 |
| 210003071 | 210010378 | 1.63 | 66 | Palliative (P) | 2021-05-20 | 2021-06-03 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100420339 |
| 210003074 | 210010381 | 1.56 | 72 | null | 2019-10-14 | 2019-11-01 | EVEROLIMUS + EXEMESTANE | 02 | null | FEC + DOCETAXEL | 101289124 |
| 210003076 | 210010382 | 1.67 | 69.3 | Palliative (P) | 2016-04-15 | 2016-04-22 | Doce + Pertuzumab + Trastuz IV Load | null | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100182857 |
| 210003077 | 210010383 | null | null | null | null | 2019-01-29 | null | 02 | null | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101241096 |
| 210003080 | 210010384 | 1.67 | 81.5 | Adjuvant (A) | 2019-06-07 | 2019-09-03 | null | null | null | CARBOPLATIN + DOCETAXEL | 101359076 |
| 210003081 | 210010385 | null | 72 | null | null | 2022-03-28 | null | 02 | null | CARBOPLATIN + PACLITAXEL | 101022581 |
| 210003084 | 210010386 | null | null | null | null | 2018-09-25 | ROSCO Trial | null | null | TRIAL UNSPECIFIED | 101656772 |
| 210003088 | 210010387 | null | null | null | 2017-06-18 | 2017-06-25 | VINORELBINE | 02 | null | VINORELBINE | 100999924 |
| 210003089 | 210010388 | 1.64 | 0 | Neo-adjuvant (N) | 2021-04-15 | 2021-04-30 | Eribulin | 01 | N | ERIBULIN | 101848035 |
| 210003090 | 210010389 | 1.69 | 71.8 | Palliative (P) | 2017-08-22 | 2020-05-17 | null | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 100973773 |
| 210003092 | 210010391 | null | null | null | 2019-03-20 | 2019-06-06 | Eribulin | 02 | null | ERIBULIN | 101342059 |
| 210003096 | 210010392 | null | 122.9 | null | 2020-05-05 | 2020-06-10 | null | N | null | FEC | 101042671 |
| 210003099 | 210010394 | 1.58 | 82.7 | Palliative (P) | 2021-06-21 | 2021-06-28 | Capecitabine | null | N | CAPECITABINE | 101132912 |
| 210003101 | 210010396 | null | null | null | null | 2021-02-08 | null | null | null | PALBOCICLIB | 100956743 |
| 210003103 | 210010397 | 1.69 | 64.85 | 02 | 2018-04-09 | 2018-04-24 | null | null | N | NAB-PACLITAXEL | 101489039 |
| 210003108 | 210010399 | 1.6 | 60.5 | null | 2016-10-14 | 2016-10-23 | Carboplatin AUC 6 - 10 | null | null | CARBOPLATIN | 101031930 |
| 210003111 | 210010400 | 1.58 | 65.1 | Adjuvant (A) | 2018-03-22 | 2018-06-12 | Eribulin | 02 | null | ERIBULIN | 100304112 |
| 210003112 | 210010401 | 0 | 89.4 | null | null | 2019-08-20 | Capecitabine | 02 | null | CAPECITABINE | 100070955 |
| 210003113 | 210010402 | null | null | null | 2021-10-30 | 2022-03-20 | CARBOPLATIN | 02 | null | CARBOPLATIN | 100480015 |
| 210003114 | 210010403 | null | null | null | null | 2020-08-18 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101455719 |
| 210003116 | 210010404 | null | null | null | 2021-04-06 | 2021-04-08 | TCH (21 day Trastuzumab) Maint | N | null | EPIRUBICIN | 100706292 |
| 210003118 | 210010405 | null | null | Neo-adjuvant (N) | 2018-04-07 | 2018-04-18 | EVEROLIMUS | null | N | PALBOCICLIB | 100910715 |
| 210003119 | 210010406 | 1.63 | 96.1 | Palliative (P) | null | 2019-07-31 | Carboplatin AUC 6 - 10 | 02 | N | ABEMACICLIB + FULVESTRANT | 101666789 |
| 210003129 | 210010409 | 1.67 | 63.8 | Neo-adjuvant (N) | null | 2019-11-26 | NAB PACLITAXEL | 02 | N | FULVESTRANT + PALBOCICLIB | 101151851 |
| 210003135 | 210010410 | null | null | null | null | 2017-05-14 | ROSCO Trial | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101066007 |
| 210003137 | 210010412 | 1.73 | 100 | Neo-adjuvant (N) | 2016-12-16 | 2017-03-03 | Pertuzumab (Maintenance) | null | N | PERTUZUMAB | 101688526 |
| 210003138 | 210010413 | null | 76.5 | Palliative (P) | null | 2018-07-02 | Letrozole + Palbociclib | null | N | ABEMACICLIB + FULVESTRANT | 100463305 |
| 210003139 | 210010414 | 1.56 | 81.2 | Curative (C) | 2017-06-09 | 2017-09-24 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100747922 |
| 210003147 | 210010417 | 1.51 | 55.9 | Adjuvant (A) | 2018-08-20 | 2018-09-10 | FEC 60 or 75 | null | N | TRASTUZUMAB DERUXTECAN | 101213383 |
| 210003148 | 210010418 | 1.69 | 65.6 | Neo-adjuvant (N) | 2019-10-17 | 2020-04-24 | null | 02 | N | TRIAL UNSPECIFIED | 100550953 |
| 210003149 | 210010419 | 1.49 | 93 | Adjuvant (A) | 2022-03-06 | 2022-03-07 | Capecitabine | null | N | CAPECITABINE | 101333903 |
| 210003152 | 210010422 | 1.66 | 71.1 | Adjuvant (A) | 2021-08-05 | 2021-08-13 | Capecitabine | 02 | N | CAPECITABINE | 101399222 |
| 210003153 | 210010423 | 1.55 | 51.8 | Palliative (P) | 2020-01-15 | 2020-01-27 | ATEZOLIZUMAB + NAB PACLITAXEL | 02 | N | TRIAL UNSPECIFIED | 101127410 |
| 210003159 | 210010425 | 1.57 | 72 | null | 2017-09-26 | 2017-10-17 | Fulvestrant + Palbociclib | 01 | null | EC | 101854038 |
| 210003163 | 210010427 | 1.63 | 71.5 | Palliative (P) | null | 2016-04-05 | null | 02 | null | CARBOPLATIN + DOCETAXEL | 100481283 |
| 210003164 | 210010428 | null | 48 | null | 2017-11-24 | 2017-12-31 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100322804 |